Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Burkitt's lymphoma: single-centre experience with modified BFM protocol.

E Harris1, S Paneesha, N Jackson

  • 1Department of Haematology, Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.

Clinical and Laboratory Haematology
|May 3, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential increase of the U.S. total fertility rate resulting from restorative treatment of unresolved subfertility: a simulation study.

Frontiers in reproductive health·2026
Same author

Early resource scarcity drives persistent transcriptional changes and vascular remodeling in the female prefrontal cortex.

bioRxiv : the preprint server for biology·2026
Same author

Experimental Test of the Ratio Method for Nuclear-Reaction Analysis.

Physical review letters·2025
Same author

Understanding context: leveraging the pragmatic robust implementation sustainability model to inform the implementation of a community-based southeastern preconception counseling intervention to improve maternal health equity.

Discover health systems·2025
Same author

A Low Albedo, Thin, Resistant Unit in Oxia Planum, Mars: Evidence for an Airfall Deposit and Late-Stage Groundwater Activity at the ExoMars Rover Landing Site.

Journal of geophysical research. Planets·2024
Same author

Effects of a synthetic analog of the bovine appeasing pheromone on the overall welfare of dairy calves from birth through weaning.

Journal of dairy science·2024
Same journal

Cystic fibrosis presenting with haematological abnormalities.

Clinical and laboratory haematology·2006
Same journal

T-cell-rich B-cell lymphoma of the spleen presenting with severe hypersplenism.

Clinical and laboratory haematology·2006
Same journal

Spontaneous splenic haematoma in a multiple myeloma patient receiving pegfilgrastim support.

Clinical and laboratory haematology·2006
Same journal

Analysis of the CDR3 region of alpha/beta T-cell receptors (TCRs) and TCR BD gene double-stranded recombination signal sequence breaks end in peripheral blood mononuclear cells of T-lineage acute lymphoblastic leukemia.

Clinical and laboratory haematology·2006
Same journal

Characterization of several amino acid transports and glutamine metabolism in MOLT4 human T4 leukemia cells.

Clinical and laboratory haematology·2006
Same journal

Osteomylelitis and necrosis of the jaw in patients treated with bisphosphonates: a comparative study focused on multiple myeloma.

Clinical and laboratory haematology·2006
See all related articles

This study modified the BFM protocol for Burkitt's lymphoma, reducing methotrexate dosage to improve tolerance. The modified regimen achieved a 75% remission rate in eight patients with aggressive non-Hodgkin's lymphoma.

Area of Science:

  • Oncology
  • Hematology
  • Clinical Medicine

Background:

  • Burkitt's lymphoma is an aggressive non-Hodgkin's lymphoma (NHL) with a poor response to standard chemotherapy.
  • Intensive chemotherapy protocols and central nervous system (CNS) prophylaxis have improved prognosis.
  • Previous treatment strategies often involve high-dose methotrexate and alkylating agents.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of a modified BFM protocol for Burkitt's lymphoma.
  • To assess the impact of reduced methotrexate dosage on treatment outcomes.
  • To determine the feasibility of this modified regimen in patients with aggressive lymphoma.

Main Methods:

  • Eight patients with Burkitt's lymphoma were treated with a modified BFM protocol.

Related Experiment Videos

  • Methotrexate dosage was reduced from 5 g/m2 to 1.5 g/m2.
  • Treatment included high-dose methotrexate, alkylating agents (ifosphamide or cyclophosphamide), and intrathecal chemotherapy. Two patients received autologous stem cell transplant.

    • Main Results:

    • The modified regimen was well tolerated with minimal toxicity.
    • Six out of eight patients (75%) achieved complete remission at a median follow-up of 16 months.
    • Two patients relapsed, one 24 months post-chemotherapy and another 1 month post-stem cell transplant.

    Conclusions:

    • A modified BFM protocol with reduced methotrexate dosage is a feasible and tolerable treatment option for Burkitt's lymphoma.
    • This approach demonstrates a high remission rate in patients with aggressive non-Hodgkin's lymphoma.
    • Further investigation is warranted to optimize treatment strategies and long-term outcomes.